To Compare Safety and Pharmacokinetic Properties of CJ-30039 and Lipidil Supra

Inclusion Criteria: * Male volunteers in the age between 20 and 55 years old * BMI(Body Mass Index) in the range of 18.5 to 25kg/m2 * Subject with no history of any significant chronic disease Exclusion Criteria: * History of clinically significant allergies, including fenofibric acid or Fenofibrate * History of clinically significant hepatic, renal, neurology, psychiatric, pulmonary, endocrine, hematologic, cardiovascular disease * History of surgery except or gastrointestinal disease which might significantly change absorption of medicines * Clinical laboratory test values are outside the accepted normal range * AST(ASpartate Transaminase), ALT(ALanine Transaminase)( \> 1.25 times to normal range * Total bilirubin \> 1.5 times to normal range * BUN(Blood Urea Nitrogen) \> 25 mg/dL or Creatinine \> 1.4 mg/dL * CK(Creatine Kinase) \> 1.25 times to normal range * Estimated GFR(Glomerular Filtration Rate) \< 80 mL/min/1.73m2 * Clinically significant vital sign * SBP(Systolic Blood Pressure) ≤ 90 mmHg or SBP ≥ 150 mmHg * DBP(Diastolic Blood Pressure) ≤ 50 mmHg or DBP ≥ 100 mmHg * History of drug abuse or positive urine screen for drugs * History of caffeine, alcohol, smoking abuse * caffeine \> 5 cups/day * alcohol \> 201g/week * smoking \> 10 cigarettes/day * Use of prescription only medicine and oriental medicine within the 14 days before dosing or use of non-prescription medicine within the 7 days before dosing * Participated in a previous clinical trial within 60 days prior to dosing * Donated blood within 60 days prior to dosing